JP2024544500A - 焦燥性興奮および他の認知症関連行動症状を治療する方法 - Google Patents

焦燥性興奮および他の認知症関連行動症状を治療する方法 Download PDF

Info

Publication number
JP2024544500A
JP2024544500A JP2024526913A JP2024526913A JP2024544500A JP 2024544500 A JP2024544500 A JP 2024544500A JP 2024526913 A JP2024526913 A JP 2024526913A JP 2024526913 A JP2024526913 A JP 2024526913A JP 2024544500 A JP2024544500 A JP 2024544500A
Authority
JP
Japan
Prior art keywords
fasudil
agitation
patient
dementia
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544500A5 (cg-RX-API-DMAC10.html
Inventor
マカリスター，トーマス
ジェイコブソン，スヴェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of JP2024544500A publication Critical patent/JP2024544500A/ja
Publication of JP2024544500A5 publication Critical patent/JP2024544500A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024526913A 2021-11-29 2022-11-15 焦燥性興奮および他の認知症関連行動症状を治療する方法 Pending JP2024544500A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163283696P 2021-11-29 2021-11-29
US63/283,696 2021-11-29
PCT/US2022/079861 WO2023097151A1 (en) 2021-11-29 2022-11-15 Methods of treating agitation and other dementia-associated behavioral symptoms

Publications (2)

Publication Number Publication Date
JP2024544500A true JP2024544500A (ja) 2024-12-03
JP2024544500A5 JP2024544500A5 (cg-RX-API-DMAC10.html) 2025-11-26

Family

ID=86540411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526913A Pending JP2024544500A (ja) 2021-11-29 2022-11-15 焦燥性興奮および他の認知症関連行動症状を治療する方法

Country Status (7)

Country Link
US (2) US20240423998A1 (cg-RX-API-DMAC10.html)
EP (1) EP4440566A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024544500A (cg-RX-API-DMAC10.html)
CN (1) CN118354769A (cg-RX-API-DMAC10.html)
CA (1) CA3236462A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024006505A (cg-RX-API-DMAC10.html)
WO (1) WO2023097151A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
WO2025024104A2 (en) * 2023-07-06 2025-01-30 Woolsey Pharmaceuticals, Inc. Method for reducing caregiver burden associated with alzheimer's disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104340D0 (sv) * 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
EP2061314A4 (en) 2006-08-10 2010-08-04 Translational Genomics Res Inst CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
CN101612157A (zh) 2008-06-26 2009-12-30 天津红日药业股份有限公司 法舒地尔诱导成年脑内源性神经干细胞再生的用途
EP2825175B1 (en) 2012-03-12 2017-07-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis
US9617214B2 (en) * 2013-11-08 2017-04-11 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
US10537567B2 (en) * 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
CN111050766A (zh) * 2017-07-21 2020-04-21 卡德门企业有限公司 Rho相关含卷曲螺旋蛋白激酶的抑制剂
EP3868408A4 (en) 2018-10-15 2022-07-06 National University Corporation Tokai National Higher Education and Research System ANTISYCHOTIC AND ITS USE
WO2021142183A1 (en) * 2020-01-09 2021-07-15 Woolsey Pharmaceuticals, Inc Methods of treating cortical dementia associated wandering
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
CA3169944A1 (en) 2020-03-25 2021-09-30 Thomas Macallister Methods of using rho kinase inhibitors to treat frontotemporal dementia
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
WO2021257122A1 (en) 2020-06-15 2021-12-23 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat vascular dementia
EP4171564A4 (en) 2020-06-25 2024-06-26 Woolsey Pharmaceuticals, Inc. METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS
EP4181925A4 (en) 2020-07-14 2024-07-31 Woolsey Pharmaceuticals, Inc. METHODS OF TREATMENT OF PROTEINOPATHIES
US11311553B1 (en) 2020-10-22 2022-04-26 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
US20220331333A1 (en) 2021-04-16 2022-10-20 Universite De Strasbourg Rhoa pathway inhibitor in the treatment of neurodevelopmental disorder or neuropsychiatric disorder
WO2022245708A1 (en) 2021-05-19 2022-11-24 Woolsey Pharmaceuticals, Inc. Methods of treating depression and anxiety
MX2023013538A (es) 2021-05-19 2023-11-27 Woolsey Pharmaceuticals Inc Metodos para tratar la depresion y la ansiedad.

Also Published As

Publication number Publication date
WO2023097151A1 (en) 2023-06-01
MX2024006505A (es) 2024-06-05
EP4440566A4 (en) 2025-10-01
US11865119B2 (en) 2024-01-09
CN118354769A (zh) 2024-07-16
EP4440566A1 (en) 2024-10-09
CA3236462A1 (en) 2023-06-01
US20230201219A1 (en) 2023-06-29
US20240423998A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
CA3073996C (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
EP3302454B1 (en) Compositions for use in treating parkinson's disease and related disorders
US11865119B2 (en) Methods of treating agitation and other dementia-associated behavioral symptoms
EP4087564B1 (en) Fasudil for use in methods of treating alzheimer's dementia associated wandering
CA3180411A1 (en) Methods of using rho kinase inhibitors to treat vascular dementia
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
US11311553B1 (en) Methods of treating 4-repeat tauopathies
JP2016502990A (ja) ボルチオキセチンとドネペジルとを含む組成物
US20240261298A1 (en) Methods of treating depression and anxiety
CA3217521A1 (en) Methods of treating depression and anxiety
EP4103187B1 (en) Fasudil for treating pseudobulbar affect
US20230405017A1 (en) Methods of using rho kinase inhibitors to treat frontotemporal dementia
JP6734469B2 (ja) ヒスタミン−３受容体インバースアゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種組合せ
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
Reuter et al. Lasmiditan hydrochloride
VanDenBerg Clinically significant interactions with cholinesterase inhibitors and other antidementia agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114